GENERALIZED MYASTHENIA GRAVIS

This study tests a daily pill called iptacopan for people with generalized myasthenia gravis, a condition causing muscle weakness. About 146 adults will receive either iptacopan or a placebo for 6 months, while continuing their usual treatments. The goal is to see if iptacopan im…

This study tests a new treatment called KYV-101, made from a patient's own immune cells, for people with generalized myasthenia gravis that hasn't improved with standard therapies. About 66 participants will receive either KYV-101 or continue their usual immunosuppressive drugs. …

This study tests a drug called rozanolixizumab in 12 children aged 2 to 17 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug is safe and tolerable. Participants receive the drug as a shot under the …

This early-phase study tests a new treatment called YTB323, a CAR-T cell therapy, for people with generalized myasthenia gravis that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease. About 15 participants will receive the…

This study tests an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. About …

This study looks at whether a planned reduction of oral steroids is safe and effective for adults with generalized myasthenia gravis who are already receiving the drug ravulizumab. About 75 participants will follow a step-by-step tapering schedule. The goal is to see if they can …

This study tests a drug called gefurulimab in 12 children (ages 6 to 17) who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how safe it is, and if it helps improve symptoms. Participants will re…

This study tests whether the drug ravulizumab can improve daily living activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR-positive). About 40 participants will receive treatment and be followed for 50 weeks. The goal is to see i…

This study tests a drug called inebilizumab in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how safe it is, and if it helps control symptoms. About 15 children will take …

This study tests an investigational drug called IMVT-1402 in 231 adults with mild to severe generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo to see if it improves daily activities and muscle strength. The goal i…

This study tests a new drug, B007, in 104 people with generalized myasthenia gravis, a condition causing muscle weakness. Participants will receive either B007 or a placebo, and researchers will measure improvements in daily activities over time. The goal is to see if B007 can be…

This study tests an experimental drug called remibrutinib against a placebo in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants must already be on standard treatments. The main goal is to see if the drug improves daily activities ov…

This study is testing how safe and effective different drug combinations are for people with myasthenia gravis, a condition that causes muscle weakness. Researchers want to find treatments that reduce side effects and improve quality of life. About 70 adults with generalized MG a…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with generalized myasthenia gravis (gMG) who still have muscle weakness. About 70 adults with a specific antibody type (AChR-Ab positive) will receive the c…

This study tests a drug called telitacicept in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants receive either the drug or a placebo for 24 weeks to see if it improves daily activities like walking and talking. The goal is to contro…

This study tests an investigational drug called zilucoplan in 8 children (ages 2-17) with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, its safety, and whether it helps control symptoms. Participant…

This study tests a new oral form of cladribine to see if it improves daily activities and muscle strength in people with generalized myasthenia gravis, a condition causing muscle weakness. About 264 adults will receive either the drug or a placebo, and researchers will track chan…

This study is testing an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and see how safe it is. Participants will receive injections and be monitored…

This study is testing a new medicine called cizutamig in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The main goal is to check if the drug is safe and how the body processes it. About 44 adults with moderate to severe symptoms who hav…

This study is a long-term registry for 500 people with generalized myasthenia gravis (gMG) who are taking or have taken C5 inhibitor therapies like Soliris or Ultomiris. Researchers will collect data on symptoms, daily living activities, and safety over time. The goal is to bette…